FDA Approves Nuplazid (pimavanserin) for Parkinson's Disease Psychosis
The FDA has approved Nuplazid (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. This is the first drug specifically approved for this indication, addressing a significant unmet need in patients with Parkinson's disease who experience psychotic symptoms. The approval was based on a 6-week randomized, placebo-controlled trial in 199 patients, which showed that Nuplazid 34 mg once daily significantly reduced the frequency and severity of hallucinations and delusions compared with placebo, as measured by the Parkinson's disease-adapted Scale for the Assessment of Positive Symptoms (SAPS-PD). Importantly, Nuplazid did not worsen motor function, a common concern with antipsychotic use in Parkinson's disease. The recommended dose is 34 mg once daily without titration, and dose adjustments are needed when coadministered with strong CYP3A4 inhibitors.
＋ Clinical Details (Mechanism · Dosing · Trial Data · Warnings)
Not reported in label.
Nuplazid is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The label does not specify dementia status; patients in the pivotal trial had PD with or without dementia and a Mini-Mental State Examination (MMSE) score of 21 or higher.
The recommended dose is 34 mg taken orally once daily, without titration. It can be taken with or without food. Capsules may be swallowed whole or opened and the entire contents sprinkled over a tablespoon of applesauce, yogurt, pudding, or a liquid nutritional supplement; consume immediately without chewing. For coadministration with strong CYP3A4 inhibitors, reduce dose to 10 mg once daily. Avoid concomitant use with strong or moderate CYP3A4 inducers.
Efficacy was demonstrated in a 6-week, randomized, placebo-controlled, parallel-group study in 199 patients with Parkinson's disease psychosis. Patients were randomized 1:1 to Nuplazid 34 mg or placebo once daily. The primary endpoint was change from baseline to Week 6 in SAPS-PD total score (range 0-45, higher = more severe). Nuplazid (n=95) showed a least-squares mean change of -5.79 vs placebo (n=90) -2.73, with a placebo-subtracted difference of -3.06 (95% CI: -4.91, -1.20). Effects were seen on both hallucinations and delusions subscales. Motor function, measured by UPDRS Parts II+III, showed no worsening with Nuplazid compared to placebo.
Contraindicated in patients with a history of hypersensitivity reaction to pimavanserin or any components. Hypersensitivity reactions including rash, urticaria, and angioedema (tongue swelling, circumoral edema, throat tightness, dyspnea) have been reported.
Nuplazid is the first FDA-approved treatment specifically for hallucinations and delusions associated with Parkinson's disease psychosis. It offers an option that does not appear to worsen motor function, which is a key advantage over other antipsychotics in this population.
View Original Abstract ↓
Intravenous tenecteplase improves functional outcomes but increases hemorrhage risk in non-large vessel occlusion acute ischemic stroke
Tenecteplase improves stroke recovery but increases bleeding risk in late treatment window
Related in Neurology
From Other Specialties
